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The major determinant of morbidity and mortality in coro-
nary artery disease is the status of myocardial function .
Thu s, the thrust of our therapy has been directed toward
maintenance of normal ventricular function and prevention
of loss of heart muscle . Although numerous interventions
have been designed to alter the balance of oxygen demand
and oxygen supply to favorably affect ventricular perform -
ance , nothing has surpas sed restoration of blood flow. In
acute myocardial infarction, coronary thrombolysis occur s
spontaneously in approximately 20% of patients in the early
hour s, and studies (1-3) have shown that lytic agents
may produce lysis in an additional 40 to 70% of patient s.
The combination of thrombolytic therap y and spontaneous
thrombolysis has achieved an early reperfusion rate of 70
to 90%. However, it is clear that " time means muscle,"
and strategies that have evolved relate to reducing the time
from acute occlusion to thrombolysis . If thrombolysis oc-
curs within 30 minutes of the acute event there is a high
salvage rate of cardiac muscle (4) ; if it occurs within 90
minutes after the event substantial benefits have been dem-
onstrated but after 3 hours the advantage diminishes (5,6).
Early thrombolysis gives an advant age in both short- and
long-term mortality. The Italian GISSI trial (7) revealed a
significant reduction in mortality-to 8.1% with intravenous
strept okinase, as compared with 15.3% in control patients ,
when treatment was instituted within I hour of the onset of
symptoms. When treatment was instituted within 3 hours,
mortality was 8.5 % in treated versus 11.9% in control pa-
tient s. The advantage was minimal after 3 hours. Similarly,
in the ISAM trial (5) after 21 days the mortality rate was
5.2% in those receiving intravenous streptokinase within 3
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hours of the onset of symptoms, as compared with 6.5% in
the placebo-treated group . As noted in this Seminar, at 7
months ' follow-up the difference in mortalit y rates had nar-
rowed to 10.9% in the streptokinase group and 11. 1% in
the placebo group (8). At 21 months , the mortality rates
were 14.4% in the streptokinase group and 16.1% in the
placebo group. These differences were not statistically sig-
nificant.
Of particular note was the significantly higher reinfarc-
tion rate in the streptokinase-treated patients (8). This was
also true in the GISSI study (7) . Clearly, early reperfusion
offered " a second chance," particularly in those treated
very early , in whom there was muscle salvage and thus an
opportunity to take advantage of this event and prevent
recurrence-that is "maximizing the advantage." This
Seminar may help us focus on ways to maximize the ad-
vantage of our second chance . The enthusiasm for percu-
taneous trans luminal coronary angioplasty as an immediate
therapy has gained great momentum (3,9) but without long-
term randomized substantiation of its benefits. It would ap-
pear that individualization of therapy will prove beneficial.
Intravenous streptokinase will be the therap y of choice
in many patients , because it can be admini stered early with-
out major facilities available. Subsequent treatment , such
as administration of intracoronary lytic agents, balloon an- ..
giopla sty, coronary artery bypass surgery and combinations
of these, may be utilized, depending on the specific situa-
tion . It is obvious from available studies (10 , II) that there
is time to individualize specific therapy in most patients ,
and that immediate angioplasty or surgery is not necessarily
mandatory. In fact , recent studies have shown significant
resolution of obstruction with lytic agents and spontaneous
continued lytic activity in 15 to 30% of patients. This dem-
onstrates the wisdom of short-term observation in selected
patients and longer term observation in others.
Carefully utilized, recombinant tissue plasminogen ac-
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tivator will increase our effectiveness in coronary throm-
bolysis (12), providing a second chance to more patients,
but at the "same time" increasing the need for diligence in
individual patient therapy to "maximize this second chance."
It is clear that, having gained the advantage, we cannot
relax our careful surveillance of a given patient. Careful
clinical follow-up with appropriate interventional tberapy->
be it medical, balloon angioplasty, laser therapy or coronary
bypass surgery-will make the most of our advantage and
should further reduce early and late morbidity and mortality
in the very large segment of the population that is at risk
for the ravages of acute myocardial infarction.
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